The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report 2025

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1986300

No of Pages : 81

Ask Your Query
Synopsis
The global NTRK Fusion Gene Positive Advanced Solid Tumor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for NTRK Fusion Gene Positive Advanced Solid Tumor in Hospitals and Clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of NTRK Fusion Gene Positive Advanced Solid Tumor include Bayer, Teva Pharmaceuticals, Empire Genomics, SeraCare Life Sciences, F. Hoffmann-La Roche, NeoGenomics Laboratories, Glaxosmithkline, OncoDNA and Merck & Co., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for NTRK Fusion Gene Positive Advanced Solid Tumor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NTRK Fusion Gene Positive Advanced Solid Tumor.
Report Scope
The NTRK Fusion Gene Positive Advanced Solid Tumor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NTRK Fusion Gene Positive Advanced Solid Tumor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NTRK Fusion Gene Positive Advanced Solid Tumor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Teva Pharmaceuticals
Empire Genomics
SeraCare Life Sciences
F. Hoffmann-La Roche
NeoGenomics Laboratories
Glaxosmithkline
OncoDNA
Merck & Co.
Daiichi Sankyo
S Deciphera Pharmaceuticals
Segment by Type
Therapeutics
Diagnostics
Segment by Application
Hospitals and Clinics
Cancer Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NTRK Fusion Gene Positive Advanced Solid Tumor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Therapeutics
1.2.3 Diagnostics
1.3 Market by Application
1.3.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Cancer Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Perspective (2019-2030)
2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Growth Trends by Region
2.2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Region (2019-2024)
2.2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2025-2030)
2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Dynamics
2.3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Industry Trends
2.3.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers
2.3.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges
2.3.4 NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue
3.1.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue (2019-2024)
3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Players (2019-2024)
3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue
3.4 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio
3.4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2023
3.5 NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Area Served
3.6 Key Players NTRK Fusion Gene Positive Advanced Solid Tumor Product Solution and Service
3.7 Date of Enter into NTRK Fusion Gene Positive Advanced Solid Tumor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Type
4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Type (2019-2024)
4.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2025-2030)
5 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Application
5.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Application (2019-2024)
5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2019-2030)
6.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024)
6.4 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2019-2030)
7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024)
7.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2019-2030)
8.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2019-2024)
8.4 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2019-2030)
9.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024)
9.4 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2019-2030)
10.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024)
10.4 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.1.4 Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Detail
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.2.4 Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Empire Genomics
11.3.1 Empire Genomics Company Detail
11.3.2 Empire Genomics Business Overview
11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.3.4 Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.3.5 Empire Genomics Recent Development
11.4 SeraCare Life Sciences
11.4.1 SeraCare Life Sciences Company Detail
11.4.2 SeraCare Life Sciences Business Overview
11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.4.4 SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.4.5 SeraCare Life Sciences Recent Development
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Detail
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.5.4 F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.5.5 F. Hoffmann-La Roche Recent Development
11.6 NeoGenomics Laboratories
11.6.1 NeoGenomics Laboratories Company Detail
11.6.2 NeoGenomics Laboratories Business Overview
11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.6.4 NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.6.5 NeoGenomics Laboratories Recent Development
11.7 Glaxosmithkline
11.7.1 Glaxosmithkline Company Detail
11.7.2 Glaxosmithkline Business Overview
11.7.3 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.7.4 Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.7.5 Glaxosmithkline Recent Development
11.8 OncoDNA
11.8.1 OncoDNA Company Detail
11.8.2 OncoDNA Business Overview
11.8.3 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.8.4 OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.8.5 OncoDNA Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.9.4 Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.9.5 Merck & Co. Recent Development
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Detail
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.10.4 Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.10.5 Daiichi Sankyo Recent Development
11.11 S Deciphera Pharmaceuticals
11.11.1 S Deciphera Pharmaceuticals Company Detail
11.11.2 S Deciphera Pharmaceuticals Business Overview
11.11.3 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.11.4 S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
11.11.5 S Deciphera Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Therapeutics
Table 3. Key Players of Diagnostics
Table 4. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2019-2024)
Table 8. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2025-2030)
Table 10. NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends
Table 11. NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers
Table 12. NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges
Table 13. NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints
Table 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Players (2019-2024)
Table 16. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2023)
Table 17. Ranking of Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players NTRK Fusion Gene Positive Advanced Solid Tumor Product Solution and Service
Table 21. Date of Enter into NTRK Fusion Gene Positive Advanced Solid Tumor Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2019-2024)
Table 25. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2025-2030)
Table 27. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Application (2019-2024)
Table 29. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Application (2025-2030)
Table 31. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2025-2030) & (US$ Million)
Table 46. Bayer Company Detail
Table 47. Bayer Business Overview
Table 48. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 49. Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 50. Bayer Recent Development
Table 51. Teva Pharmaceuticals Company Detail
Table 52. Teva Pharmaceuticals Business Overview
Table 53. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 54. Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 55. Teva Pharmaceuticals Recent Development
Table 56. Empire Genomics Company Detail
Table 57. Empire Genomics Business Overview
Table 58. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 59. Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 60. Empire Genomics Recent Development
Table 61. SeraCare Life Sciences Company Detail
Table 62. SeraCare Life Sciences Business Overview
Table 63. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 64. SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 65. SeraCare Life Sciences Recent Development
Table 66. F. Hoffmann-La Roche Company Detail
Table 67. F. Hoffmann-La Roche Business Overview
Table 68. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 69. F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 70. F. Hoffmann-La Roche Recent Development
Table 71. NeoGenomics Laboratories Company Detail
Table 72. NeoGenomics Laboratories Business Overview
Table 73. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 74. NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 75. NeoGenomics Laboratories Recent Development
Table 76. Glaxosmithkline Company Detail
Table 77. Glaxosmithkline Business Overview
Table 78. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 79. Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 80. Glaxosmithkline Recent Development
Table 81. OncoDNA Company Detail
Table 82. OncoDNA Business Overview
Table 83. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 84. OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 85. OncoDNA Recent Development
Table 86. Merck & Co. Company Detail
Table 87. Merck & Co. Business Overview
Table 88. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 89. Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 90. Merck & Co. Recent Development
Table 91. Daiichi Sankyo Company Detail
Table 92. Daiichi Sankyo Business Overview
Table 93. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 94. Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 95. Daiichi Sankyo Recent Development
Table 96. S Deciphera Pharmaceuticals Company Detail
Table 97. S Deciphera Pharmaceuticals Business Overview
Table 98. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 99. S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024) & (US$ Million)
Table 100. S Deciphera Pharmaceuticals Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type: 2023 VS 2030
Figure 3. Therapeutics Features
Figure 4. Diagnostics Features
Figure 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application: 2023 VS 2030
Figure 7. Hospitals and Clinics Case Studies
Figure 8. Cancer Centers Case Studies
Figure 9. Others Case Studies
Figure 10. NTRK Fusion Gene Positive Advanced Solid Tumor Report Years Considered
Figure 11. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region: 2023 VS 2030
Figure 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Players in 2023
Figure 15. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2023
Figure 17. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2019-2030)
Figure 19. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2019-2030)
Figure 23. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2019-2030)
Figure 31. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2019-2030)
Figure 39. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2019-2030)
Figure 43. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Bayer Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 46. Teva Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 47. Empire Genomics Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 48. SeraCare Life Sciences Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 49. F. Hoffmann-La Roche Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 50. NeoGenomics Laboratories Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 51. Glaxosmithkline Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 52. OncoDNA Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 53. Merck & Co. Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 54. Daiichi Sankyo Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 55. S Deciphera Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock